Showing 15 posts of 552 posts found.

covid_cell_1’s weekly COVID-19 news round-up

November 4, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, GSK, Sanofi, UK, US, remdesivir

As European nations fall one by one back into lockdown, hopes weigh heavily on a vaccine to pave a path …


Sanofi angles to buy Kiadis for €308 million

November 2, 2020
Sales and Marketing Sanofi, kiadis, pharma

Sanofi has announced it is poised to buy out Amsterdam-based biopharma firm Kiadis in an all-cash public offer of €308 …


GSK and Sanofi promise 200m COVID-19 vaccines to international COVAX initiative

October 28, 2020
Manufacturing and Production, Research and Development COVAX, COVID-19, GSK, Sanofi

Sanofi and GSK have committed 200 million doses of their adjuvanted recombinant protein-based COVID-19 vaccine to the COVAX Facility, a …


Sanofi’s Dupixent shows strength at Phase 3 in eosinophilic esophagitis

October 27, 2020
Manufacturing and Production Dupixent, Sanofi, pharma

Sanofi has lifted the curtain on new Phase 3 data for Dupixent (dupilumab), showing that the drug met all of …


Sanofi’s Dupixent chalks up CHMP recommendation for paediatric severe atopic dermatitis

October 19, 2020
Sales and Marketing Dupixent, EMA, Sanofi, atopic dermatitis

Sanofi’s interleukin-4 and -13 inhibitor Dupixent (dupilumab) has been given the recommendation of the European Medicines Agency’s Committee for Medicinal …


NICE approves Sanofi’s Sarclisa combo for relapsed/refractory multiple myeloma

October 16, 2020
Medical Communications, Sales and Marketing NICE, Sanofi, Sarclisa, multiple myeloma

Sanofi’s Sarclisa (isatuximab) has secured a recommendation from NICE for routine use on the NHS in England and Wales as …


Promising Phase 2 data for Sanofi and Regeneron’s PD-1 inhibitor Libtayo in locally advanced basal cell carcinoma

September 18, 2020
Medical Communications, Research and Development Cancer, ESMO 2020, Libtayo, Regeneron, Sanofi, pharma

Promising Phase 2 data has been released at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 for Sanofi …


Extension study reveals Dupixent’s benefit can last up to three years in moderate-to-severe asthma

September 8, 2020
Manufacturing and Production, Research and Development Dupixent, Sanofi, asthma, pharma

New findings have been revealed from an extension study of Sanofi’s interleukin-4 (IL-4) and interleukin-13 (IL-13) inhibitor Dupixent (dupilumab) in …


President of Sanofi France expects COVID-19 vaccine to be priced below ten Euros

September 7, 2020
Sales and Marketing COVID-19, GSK, Sanofi

The President of Sanofi France expects the coronavirus vaccine it is developing with GlaxoSmithKline to be priced under 10 Euros.  …


Sanofi halts Phase 3 trial of Kevzara as a COVID-19 treatment

September 1, 2020
Manufacturing and Production COVID-19, Sanofi, Vaccine, pharma

Sanofi is halting clinical trials treating serious COVID-19 patients with its Kevzara drug after data on its efficacy proved inconclusive.The …


Sanofi to buy Principia Biopharma for $3.4 billion

August 17, 2020
Sales and Marketing MS, Sanofi

Sanofi is set to buy California based Principia Biopharma in a deal that is worth $3.4 billion. This deal means …


Sanofi indicted on manslaughter charges over its epilepsy drug Depakine

August 4, 2020
Manufacturing and Production Sanofi, Vaccine

Sanofi is being investigated for manslaughter in France over the deaths of four babies whose mothers took its anti-epilepsy medication …


US Government commits $2.1bn to GSK and Sanofi’s COVID-19 vaccine candidate

July 31, 2020
Medical Communications, Research and Development COVID-19, GSK, Sanofi, US, Vaccine

The US Government has announced additional funding into Sanofi and GlaxSmithKline’s efforts to develop a recombinant protein-based vaccine to the …

Sanofi’s nirsevimab nails study goals for prevention of respiratory syncytial virus in infants

July 30, 2020
Research and Development Sanofi, nirsevimab, pharma

Sanofi’s nirsevimab met its goals in a Phase 2b study, the company has revealed, investigating its efficacy in the prevention …


UK Government secures 60 million doses of Sanofi and GSK’s COVID-19 vaccine

July 29, 2020
Research and Development, Sales and Marketing COVID-19, GSK, Sanofi, UK government, pharma

The UK Government has sealed another deal to procure an effective COVID-19 vaccine for its citizens, partnering up with Sanofi …

Latest content